[THE INVESTOR] The Ministry of Food and Drug Safety announced on Oct. 4 that it will maintain its conditional approval for sale of
Hanmi Pharmaceutical’s targeted cancer therapy Olmutinib, on condition that patients are made aware of the details of possible side effects and give their consent.
Related article :
Probes on Hanmi Pharma likely to focus on alleged insider tradingFollowing a report that one patient died from a severe skin-related side effects toxic epidermal necrolysis during the drug’s clinical trials in April, Central Pharmaceutical Affairs Advisory Committee has discussed on necessity to take further steps to ensure safety of patients prescribed with the drug that was approved for sales in South Korea in May.
By Hwang You-mee (
glamazon@hearldcorp.com)
